Transforming growth factor beta-resistant natural killer cells

TGF-β imprinted NK cells, generated through chronic activation with TGF-β cytokines, address supply and proliferation limitations, enhancing their antitumor efficacy by resisting TGF-β suppression and maintaining cytokine secretion.

JP7591406B2Active Publication Date: 2024-11-28RES INST AT NATIONWIDE CHILDRENS HOSPITAL
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2020562093
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-01-30
Filing Date
2019-01-29
Publication Date
2024-11-28
Estimated Expiration
2039-01-29

AI Technical Summary

Technical Problem

The development of NK cell adoptive transfer procedures is hampered by the limited supply of viable cells, contamination issues, poor proliferation in vitro, and susceptibility to TGF-β immunosuppression, which inhibits their antitumor activity in the tumor microenvironment.

Method used

Generation of TGF-β imprinted NK (TGFβi NK) cells through chronic in vitro activation with TGF-β superfamily cytokines, such as IL-12/15/18, to enhance cytotoxicity and cytokine secretion while resisting TGF-β suppression.

Benefits of technology

TGFβi NK cells maintain increased cytokine secretion and cytotoxicity, overcoming TGF-β inhibition, and effectively control tumor growth both in vitro and in vivo.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591406000001
    Figure 0007591406000001
  • Figure 0007591406000002
    Figure 0007591406000002
  • Figure 0007591406000003
    Figure 0007591406000003
Patent Text Reader

Abstract

NK cells with low SMAD3 expression and an altered gene expression profile that result in high cytokine expression and TGF-β superfamily resistance are described, herein referred to as TGF-β superfamily-imprinted natural killer cells (TGFβi NK cells). Methods for treating cancer or infectious diseases in a subject in need thereof are described. The methods include administering to the subject a therapeutically effective number of TGFβi NK cells. Methods for producing TGFβi NK cells by in vitro activation of natural killer cells in the presence of TGF-β superfamily cytokines are described.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 623,682, filed January 30, 2018, which is incorporated by reference in its entirety. [Background technology]

[0002] Clinicians have sought to use natural killer (NK) cells for adoptive transfer because of their ability to recognize and kill tumor cells without the need for any specific tumor cell marker. Alizadeh et al., Clin Cancer Res. 16(13): 3399-3408 (2010). However, the development of NK cell adoptive transfer procedures has been hampered by the limited supply of viable cells. NK cells are only a small proportion of cells in the blood, and isolation from a typical blood draw does not yield many cells. Furthermore, NK cells must be purified to avoid contaminating PBMCs such as T and B cells by CD3 and CD19 depletion, respectively. Childs et al., American Society of Hematology (ASH) Education Book, vol. 2013 no. 1 234-246 (2013). This is a necessary step for allogeneic transplants, where the presence of T and B cells increases the risk of graft-versus-host disease (GVHD), but further reduces the NK cell yield.

[0003] NK cells do not proliferate well in vitro compared to other types of cells, mainly due to early senescence. Furthermore, by using the most effective methods, NK cells are highly susceptible to telomere shortening and senescence after only a few passages. Denman et al.,PLoS ONE 7(1): e30264(2012). The most effective method to increase NK cell viability and proliferation in vitro is to co-culture with feeder cells. Commonly used feeder cells for NK cell expansion include irradiated peripheral blood mononuclear cells (PBMCs), Epstein-Barr virus transformed lymphoblastoid cell lines (EBV-LCLs), genetically modified K562 cells constitutively expressing IL-15 or 21, and other irradiated tumor cell lines. Berg et al.,Cytotherapy,11(3):34l-55(2009). Co-culturing with feeder cells significantly increases NK cell viability and proliferation with a population expansion of 1,000- to 50,000-fold.

[0004] Immunotherapy holds great promise for improving outcomes in cancers such as osteosarcoma (OS), where survival has not improved over the past 30 years. OS, including chemotherapy-resistant OS, are easily killed in vitro by both autologously and allogeneically activated NK cells. However, the tumor microenvironment in OS and other solid tumors has elevated levels of the highly immunosuppressive cytokine, transforming growth factor beta (TGF-β). Lamora et al., Clin Cancer Res 20:5097-5112 (2014); Xu et al., DNA Cell Biol, 33:802-806 (2014). The addition of a blocking antibody against TGF-β improved the efficacy of dendritic cell vaccines in OS (Kawano et al., Clin Orthop Relat Res., 470:2288-2294 (2012)), providing proof of principle that TGF-β is actively inhibiting immunotherapy in OS.

[0005] TGF-β inhibition of NK cell function is multifaceted. TGF-β regulates the development of NK cells and subsequently negatively affects their function once they reach maturity. TGF-β promotes the immature NK cell lineage by preventing the progression of NK cells to CD16+ NK cells. TGF-β can also induce former CD16+ NK cells to become CD16-. Keskin et al.,Proc Natl Acad Sci USA,104:3378-3383(2007). In addition, mice expressing dominant-negative TGFβR in NK cells have increased numbers of mature NK cells compared to wild-type mice. Viel et al.,Science signaling 9:ral9(2016).

[0006] In mature NK cells, TGF-β inhibits antitumor activity through multiple mechanisms. TGF-β reduces IL-2 and IL-15 induces NK cell proliferation (Wilson et al., PloS one 6:e22842(2011)), and IL-15 induces mTOR activation. Viel et al., Sci Signal.,16;9(4l5):ral9(2016). TGF-β also inhibits IFNγ secretion, which is important for stimulating the adaptive immune system and can render tumors susceptible to NK cell lysis. TGF-β inhibits IFNγ both directly and indirectly. SMAD3 can also inhibit IFNγ indirectly by directly binding to the IFNγ promoter and by reducing the expression of IFNγ-promoting transcription factors, T-bet, and E4BP4. Tang et al., Nat Commun,8:14677(2017). However, TGF-β-mediated inhibition of IFNγ secretion could be partially alleviated by preincubation of NK cells with IL-12, IL-15 or IL-18. Yu et al., Immunity, 24:575-590(2006). Furthermore, TGF-β also inhibits TNFα and GM-CSF secretion and regulates chemokine receptor expression to promote the retention of NK cells in the bone marrow. Castriconi et al., J Immunol, 190:5321-5328(2013).

[0007] Specifically, TGF-β mediates its inhibition of NK cytotoxicity by reducing granzyme and perforin secretion and the expression of the following activating receptors: NKG2D, NKp30, KIRs, DNAM-1, NKp44, TRAIL, and CD16, which inhibit NK cell recognition of malignant cells expressing their cognate ligands.

[0008] There are several approaches to generate NK and T cells resistant to TGF-β. These include cells expressing dominant negative TGFβRII and combination therapy using TGF-β small molecule inhibitors together with immune-based therapy. Importantly, all of these methods have demonstrated improved efficacy of NK and T cell therapy in vitro and in vivo. Wallace et al., Clin Cancer Res., 14(12):3966-74(2008); Bollard, C., Blood, 99:3179-3187(2002). However, broad-spectrum inhibition of TGF-β has the potential for adverse side effects; TGF-β signaling is context-dependent and can have both tumor-promoting and tumor-suppressing effects. For example, inhibition of TGF-β in mouse models increases the number of circulating tumor cells (Wrzesinski et al., Clin Cancer Res., 13:5262-5270 (2007)), and broad-spectrum inhibition of TGF-β results in severe autoimmune disease. Li et al., Immunity 25:455-471 (2006). Therefore, inhibition of TGF-β should be done with caution and only after determining the responsiveness of the tumor to TGF-β. Therefore, non-systemic methods of generating innate TGF-β resistance are promising alternatives to avoid the adverse effects that systemic TGF-β inhibition may have. Summary of the Invention

[0009] Many types of cancer reduce NK cell killing by the release of TGF-β. We have developed a non-genetic method to educate (imprint) NK cells to become resistant to TGF-β. TGF-β imprinted NK (TGFβi NK) cells were generated by adding TGF-β during stimulation of NK cells with IL-12 / 15 / 18. TGFβi NK maintained their cytotoxicity after stimulation better than normal NK cells. In addition, TGFβi NK cells cultured with TGF-β increased secretion of IFN-γ, TNF-α, and GM-CSF, which can increase tumor killing and broadly stimulate adaptive immune responses. The increased cytokine secretion persists for more than a month. Resistance to TGF-β persists for at least one week in vitro and is mediated by SMAD3 downregulation.

[0010] The present invention may be more readily understood with reference to the following drawings. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 provides graphs showing that NK cell activation with parental (unmodified) K562 in the presence of TGFβ induces TGFβi NK cells with cytokine hypersecretion in response to tumor targets. NK cells were stimulated weekly with K562 and cultured in medium containing IL-2 (control) or IL-2 and 10 ng / mL TGFβ (TGFβi) for 14 days. After culture, IFNγ and TNFα secretion was assessed in the supernatants after coculture with MG63 tumor targets. Lines and bars represent mean ± standard deviation. Statistical significance was determined by two-way repeated measures ANOVA with Holm-Sidak's multiple comparison test for all other graphs. *p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001. [Diagram 2]Figure 2 provides a graph showing that NK cell activation with proinflammatory cytokines in the presence of TGFβ induces TGFβi NK cells with cytokine hypersecretion in response to tumor targets. NK cells were activated overnight with IL-12, -15, and -18 (10 ng / mL, 50 ng / mL, and 50 ng / mL, respectively) with or without IL-2 and TGFβ, followed by culture in IL-15 (1 ng / mL) with or without IL-2 and TGFβ. After 7-14 days of culture, antitumor IFNγ and TNFα production in response to MG63 was measured by intracellular flow cytometry (n-4). Percent IFNγ+ and TNFα+ NK cells were normalized to no targets. Individual data points are shown for all. Statistical significance was determined by two-way repeated measures ANOVA with Holm-Sidak's multiple comparison test for all other graphs. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. [Diagram 3] FIG. 3 provides a graph showing that NK cell expansion with K562 mbIL-l5 (clone 4) feeder cells in the presence of TGFβ induces TGFβi NK cells with cytokine hypersecretion in response to tumor targets. After 14 days of expansion with feeder cells with (TGFβi) or without (control) TGFβ, NK cells were rested overnight in 50 IU / mL IL-2 with or without 10 ng / mL TGFβ. NK cells were then co-cultured with tumor targets in the same medium and supernatants were collected to measure cytokine secretion. Control, black; TGFβi, red. Statistical significance was determined by two-way repeated measures ANOVA with Holm-Sidak's multiple comparison test for all others. *p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001. [Figure 4]FIG. 4 provides a graph showing that NK cell expansion with K562 mbIL-21 feeder cells in the presence of TGFβ induces TGFβi NK cells with cytokine hypersecretion in response to tumor targets. After 14 days of expansion with feeder cells with (TGFβi) or without (control) TGFβ, NK cells were rested overnight in 50 IU / mL IL-2 with or without 10 ng / mL TGFβ. NK cells were then co-cultured with tumor targets in the same medium and supernatants were collected to measure cytokine secretion. Black, control; red, TGFβi. Statistical significance was determined by two-way repeated measures ANOVA with Holm-Sidak's multiple comparison test for all others. *p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001. [Diagram 5] Figure 5 provides a graph showing that addition of TGFβ to generate TGFβi NK cells does not reduce proliferation capacity in expansion cultures with K562 mbIL-2l (CSTX002) feeder cells. NK cells were expanded for 14 days on feeder cells with (TGFβi) or without (control) TGFβ in paired cultures from 5 donors starting with the same number of cells on day 0. The total number of viable cells after 14 days is shown and normalized to control NK cells for each paired expansion. Not significant by Student's paired t-test. [Figure 6]FIG. 6 provides graphs showing that TGFβi NK cells maintain cytokine hypersecretion against tumor cells for several weeks. A) TGFβi and control NK cells expanded with parental K562 feeder cells for 14 days (expansion) or expanded and rested for an additional 7 days (rest) were co-cultured with MG63 target cells and supernatants were assessed for cytokine secretion. B) In a similar experiment, cytokine secretion against MG63 with K562mbIL-21 expanded control and TGFβi NK cells was assessed at days 7 and 14 of expansion and again after 21, 35, and 47 days of rest. Medians are shown with minimum to maximum whiskers. Black, control, red, TGFβi. Statistical significance was determined by paired t-test. *p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001 [Figure 7] Figure 7 provides a graph showing that TGFβi NK cells exhibit cytokine hypersecretion against multiple cancer types. After 14 days of growth under control conditions or with TGFβ present to induce TGFβi NK cells, NK cells were rested overnight with or without IL-2 or TGFβ. NK cells were then co-cultured with tumor targets in the same fresh medium for 3 hours, and supernatants were collected to measure IFNγ and TNFα cytokine secretion. Individual data points are shown for DAOY (medulloblastoma, n=12) and CHLA-255 (neuroblastoma, n=5). Lines and bars represent the mean ± standard deviation. [Figure 8] 8 provides a graph showing that TGFβi NK cells show dramatic downregulation of the TGFβi-signaling protein, SMAD3. After 14 days of expansion under control conditions or with TGFβ present to induce TGFβi NK cells, NK cells were assessed for protein expression of SMAD3 and E4BP4 by Western blot (n=4). [Figure 9]Figure 9 provides a graph showing that TGFβi NK cells hypersecrete GM-CSF, TNFα, and IFNγ. Control and TGFβi NK cells were stimulated with 10 μg / mL PHA at 2×10e6 NK cells / mL for 4 hours and cytokine secretion was measured. Lines and bars represent mean ± standard deviation. Statistical significance was determined by paired t-test. [Figure 10] FIG. 10 provides a graph showing that TGFβi NK cells grown with parental K562 have similar cytotoxicity to control NK cells. Control and TGFβi NK cytotoxicity was measured using a 4-hour calcein-release cytotoxicity assay after overnight treatment with IL-2 alone or IL-2 and TGFβ. Lines and bars represent mean values ​​± standard deviation. Statistical significance was determined by two-way repeated measures ANOVA with Holm-Sidak's multiple comparison test. *p≦0.05, **p≦0.01, ***p≦0.001, ****p≦0.0001. [Figure 11] FIG. 11 provides a graph showing that expanded TGFβi NK cells control tumor growth better than control expanded NK cells in a mouse model of osteosarcoma. Treatment of mice with TGFβi NK cells expanded on K562mb IL-21 feeder cells significantly reduces the growth of the 143b osteosarcoma cell line in the lungs of NSG mice, but not control NK cells. [Figure 12]FIG. 12 provides a graph showing that TGFβi NK cells have a gene expression profile that distinguishes them from standard expanded NK cells. Standard and TGFβi NK cells were grown in pairs on CSTX002 from four donors. mRNA was isolated and subjected to RNA sequencing. The top 100 differentially expressed genes were identified. A) Principal component analysis was performed on the 1n(x+1) transformed original values. Unit variance scaling was applied to the columns; SVD with imputation is used to calculate the principal components. The X and Y axes show Principal Component 1 and Principal Component 2, which explain 95.4% and 1.6% of the total variance, respectively. TGFβi NK cells are identified with red boxes. >95% of the variance is due to TGFβ imprinting, while <2% is a result of donor variation. B) Clustering analysis was performed on the same log-transformed data. Columns are centered; unit variance scaling was applied to the columns. Both the rows and columns are clustered using correlation distance and average linkage methods. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Detailed Description The present invention provides TGF-β imprinted natural killer (TGFβi NK) cells that are highly cytotoxic, produce high levels of cytokines, and are resistant to the TGF-β superfamily of immunosuppressive cytokines. These cells can be prepared by chronic in vitro activation of natural killer cells in the presence of TGF-β superfamily cytokines. The present invention also provides a method of treating cancer or an infectious disease in a subject in need thereof by administering to the subject a therapeutically effective number of TGFβi NK cells.

[0013] definition For clarity in understanding and ease in reference, a list of terms used throughout the Brief Description section and the remainder of this application is compiled here. Some of the terms are well known throughout the field and are defined herein for clarity, while some of the terms are unique to this application and therefore must be defined for a proper understanding of this application.

[0014] "A" or "an" as used herein means one or more than one; at least one. When the plural is used herein, it generally includes the singular.

[0015] Also herein, the recitation of numerical ranges by endpoints includes all numbers subsumed within that range (eg, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0016] As used herein, the term "subject" can refer to any warm-blooded organism, including, but not limited to, humans, rats, mice, dogs, goats, sheep, horses, monkeys, apes, pigs, rabbits, cows, etc. When the term is used in the context of a subject needing or requiring the compositions of the present application, the term may also be referred to as a "subject in need thereof" and includes subjects who have been clinically diagnosed (e.g., by a medical professional, e.g., a physician) as needing the compositions of the present application, subjects suspected of needing the compositions of the present application, subjects at risk for a disease or condition, and subjects who may benefit from the compositions of the present application, as well as subjects already suffering from a disease or condition and who would benefit from the compositions of the present application.

[0017] As used herein, the term "pharmacologically acceptable" refers to those compounds, materials, compositions and / or dosage forms that are suitable, within the scope of sound medical judgment, for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0018] The term "therapeutically effective" is intended to refer to the number or amount of agents that will achieve the goal of reducing disease severity while avoiding harmful side effects such as those typically associated with alternative therapies.Therapeutically effective amounts may be administered in one or more doses.Therapeutically effective treatments include treatments that improve the quality of life of subjects, even if they do not improve disease outcomes by themselves.

[0019] In general, an "effective amount" refers to an amount that provides a desired local or systemic effect effective to stimulate cytokine formation, including achieving a specific desired effect as described herein, for example, an effective amount is an amount sufficient to effect a beneficial or desired clinical result.

[0020] "Treat," "treating," or "treatment" are used broadly in the context of the present invention, and each such term encompasses, inter alia, preventing, ameliorating, inhibiting, or curing a deficiency, dysfunction, disease or other deleterious process, including those that impede and / or result from therapy. In various embodiments, symptoms of a disease or disorder are alleviated by at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, or at least 50%.

[0021] As used herein, the term "administration" refers to the placement of a composition (e.g., a cell composition) into a subject by a method or route that results in at least partial localization of the composition at a desired site, thereby producing a desired effect. The resistant natural killer cells or compositions described herein can be administered by any suitable route known in the art, including, but not limited to, oral or parenteral routes, including intravenous, intramuscular, subcutaneous, transdermal, airway (aerosol), pulmonary, nasal, rectal and topical (including buccal and sublingual) administration.

[0022] As used herein, the term "cytokine" refers to small proteins (approximately 5-20 kDa) that are important in cell signaling and in certain immune regulation. Examples of cytokines include chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.

[0023] Therapy using TGFβi NK cells In one embodiment, the present invention provides a method for treating cancer or an infectious disease in a subject in need thereof. The method comprises administering to the subject a therapeutically effective number of TGF-β imprinted natural killer (TGFβi NK) cells. As described herein, TGFβi NK cells can be more effective and longer lasting in vivo compared to typical expanded natural killer cells, since their resistance to cytokines of the TGF-β superfamily protects them from suppression by the immune system.

[0024] As used herein, "natural killer cells" ("NK cells") refer to a type of cytotoxic lymphocyte of the immune system. NK cells provide a rapid response to virus-infected cells and respond to transformed cells. Typically, immune cells detect peptides from pathogens presented by major histocompatibility complex (MHC) molecules on the surface of infected cells, triggering cytokine release and resulting in lysis or apoptosis. However, NK cells are unique because they have the ability to recognize stressed cells regardless of whether peptides from the pathogen are present on the MHC molecule. They were named "natural killer" because they are the first that do not require prior activation to kill targets. NK cells are known to be large granular lymphocytes (LGLs) and differentiate and mature in the bone marrow, from which they then enter into the circulation.

[0025] The present invention includes NK cells that are resistant to cytokines of the transforming growth factor beta (TGF-β) superfamily, as well as methods of making and using such resistant NK cells. The TGF-β superfamily is a large group of structurally related cell regulatory proteins. TGF-β are multifunctional peptides that control proliferation, differentiation and other functions in many cell types. TGF-β-1 is a 112 amino acid residue peptide derived from proteolytic cleavage from the C-terminus of a precursor protein. These proteins interact with a conserved family of cell surface serine / threonine-specific protein kinase receptors and generate intracellular signals using a conserved family of proteins called SMADs. Major subfamilies of the TGF-β superfamily include the TGF-β subfamily (including TGF-β 1-4 isoforms), decapentaplegic Vg-related (DVR)-related proteins (e.g., bone morphogenetic proteins), growth differentiation factors (e.g., GDF-1 through GDF-15), and the activin and inhibin subfamilies. In some embodiments, the TGFβi NK cells are resistant to TGF-β.

[0026] TGFβi NK cells can be used to treat cancer or infectious diseases in a subject. Typically, TGFβi NK cells are administered by adoptive transfer of cells. In some embodiments, the subject has been diagnosed with cancer. Cancer, as defined herein, is a disease based on the development of cells that contain genetic damage that results in relatively uncontrolled proliferation of the cells. The genetic damage present in the cancer cells is maintained as a genetic trait in subsequent generations of the cancer cell line. The cancer treated by the method of the present invention can be any of the forms of cancer known to those skilled in the art or described herein. Cancers that manifest as both solid tumors and cancers that instead form non-solid tumors, typically seen in leukemias, can be treated. The present invention provides methods of treating subjects afflicted with a variety of different types of cancer, including carcinomas, sarcomas, and lymphomas.

[0027] In some embodiments, the cancer to be treated is a leukemia (e.g., acute lymphoblastic leukemia; acute myeloid leukemia; chronic myeloid leukemia, chronic lymphocytic leukemia), myelodysplastic syndrome, lymphoma (e.g., B-cell non-Hodgkin's lymphoma, Hodgkin's lymphoma, T-cell lymphoblastic lymphoma, anaplastic large cell lymphoma), solid tumor (e.g., breast cancer, prostate cancer, gastric cancer, colon cancer, hepatocellular carcinoma, nasopharyngeal carcinoma, neuroblastoma, high-grade glioma), sarcoma (e.g., Ewing's sarcoma, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, osteosarcoma). In further embodiments, the cancer is selected from the group consisting of leukemia, lymphoma, rhabdomyosarcoma, brain cancer, and bone cancer.

[0028] The efficacy of cancer treatment may be measured by assessing the reduction in tumor burden or tumor growth in a subject in response to administration of TGFβi NK cells. The reduction in tumor burden may represent a direct reduction in mass, or it may be measured in terms of tumor growth delay, which is calculated by subtracting the average time for a control tumor to grow to a certain volume from the time required for a treated tumor to grow to the same volume.

[0029] In other embodiments, the subject to be treated has an infectious disease. TGFβi NK cells have a wide range of systemic effects and can be used to treat infections caused by a variety of different microorganisms. As used herein, the term "infectious disease" is meant to include all diseases caused by infection with viruses, pathogenic bacteria or fungi, and can be transmitted through respiratory tract, blood, or skin contact. Non-limiting examples of such infectious diseases include, but are not limited to, hepatitis B, hepatitis C, human papilloma virus (HPV) infection, human immunodeficiency disease (HIV), cytomegalovirus infection, viral respiratory disease, influenza, etc.

[0030] TGF-β imprinted natural killer cells Another aspect of the present invention provides natural killer (NK) cells or NK cell lines cultured in the presence of TGF-β superfamily cytokines, referred to herein as TGFβi NK cells. This includes NK cells or cell lines produced by the methods described herein, and compositions comprising the NK cells provided herein. In certain aspects, the compositions are pharmaceutical compositions comprising one or more of the NK cells or cell lines provided herein. In some embodiments, the TGFβi NK cells exhibit increased resistance to TGF-β.

[0031] The TGFβi NK cells can be allogeneic or autologous. In some embodiments, the NK cells are mammalian NK cells. Examples of "mammals" or "mammals" include primates (e.g., humans), dogs, cats, rodents, pigs, ruminants, and the like. Specific examples include humans, dogs, cats, horses, cows, sheep, goats, rabbits, guinea pigs, rats, and mice. In certain embodiments, the mammalian NK cells are human NK cells.

[0032] TGFβi NK cells exhibit a number of characteristics that distinguish them from naturally occurring NK cells. In some embodiments, the NK cells or cell lines exhibit increased resistance to TGF-β. In other embodiments, the NK cells produce increased amounts of interferon-γ (IFN-γ), and / or tumor necrosis factor-α (TNF-α), and / or granulocyte-macrophage colony-stimulating factor (GM-CSF). In further aspects, the NK cells exhibit reduced levels of SMAD family member 3 (SMAD3) protein and / or transforming growth factor beta receptor III (TGFBR3) protein. SMAD proteins receive their name as contractions of the names C. elegans Sma and Drosophila Mad (Derynck et al., Cell, 95(6), p737-740, 1998) and are transcriptional activators of the TGF-β response.

[0033] TGFβi NK cells exhibit a number of characteristics that distinguish them from naturally occurring NK cells. In some embodiments, the NK cells have a gene expression profile substantially similar to that shown in FIG. 12. A gene expression profile that is substantially similar is one in which the gene expression is within 10% of that shown. In some embodiments, the TGFβi NK cells produce increased amounts of one or more of IFN-γ, TNF-α, and GM-CSF proteins. In some embodiments, the NK cells or cell lines exhibit increased expression of SCUBE1, MY07A, KLF3, WIPF3, and EPHA1.

[0034] TGFβi NK cells exhibit a number of characteristics that distinguish them from naturally occurring NK cells. In some embodiments, TGFβi NK cells exhibit reduced levels of SMAD3 protein and / or TGFBR3 protein. In some embodiments, NK cells or cell lines exhibit reduced expression of CD300A, SGSM1, SMAD3, TBX21 and GZMK, TGFBR3 and GZMA.

[0035] Generation of TGF-β-superfamily imprinted natural killer (TGFBi NK) cell lines Another aspect of the present invention provides a method of producing a TGF-β-superfamily imprinted natural killer (TGFβi NK) cell line, comprising in vitro activation of natural killer cells in the presence of a TGF-β-superfamily cytokine. Further, the method can include isolating or separating one or more TGFβi NK cells produced by the method provided herein. Additionally, the method can further include culturing one or more TGFβi NK cells. In some embodiments, a TGFβi NK cell line is produced. In some embodiments, the TGFβi NK cell line is expanded in the presence of TGF-β. A cell line is a plurality of cells that can be maintained in cell culture.

[0036] Expansion (i.e., activation) refers to the ex vivo expansion of NK cells, which increases the NK cell population. NK cells can be expanded, for example, from peripheral blood mononuclear cells. However, NK cells can also be expanded from other types of cells, such as hematopoietic stem or progenitor cells. Primary blood or stem cells can be isolated from a variety of different sources, such as placenta, umbilical cord blood, placental blood, peripheral blood, spleen, or liver. Expansion occurs in cell culture medium. Suitable cell culture media are known to those skilled in the art and include, but are not limited to, Basal Eagle's Medium (BME), Dulbecco's Modified Eagle's Medium (DMEM), Glasgow Minimum Essential Medium (GMEM), Dulbecco's Modified Eagle's Medium / Nutrient Mixture F-12 Ham's (DMEM / F-12), Minimum Essential Medium (MEM), Iscove's Modified Dulbecco's Medium (IMDM), Nutrient Mixture F-10 Ham's (Ham's F-10), Nutrient Mixture F-12 Ham's (Ham's F-12), RPMI-1640 Medium, William's Medium E, STEMSPAN® (catalog number Stem Cell Technologies, Vancouver, Canada), Glycostem Basal Growth Medium (GBGM®), AIM-V® Medium (Invitrogen), X-VIVO™ 10 (Lonza), X-VIVO™ 15 (Lonza), OPTMIZER (Invitrogen), STEMSPAN® H3000 (STEMCELL Technologies), CELLGRO COMPLETE™ (Mediatech) or any modified variant or combination thereof.

[0037] As used herein, the term "feeder cells" refers to cells that do not have the ability to divide and grow, but have metabolic activity and thus produce various metabolic products to support the growth of target NK cells. Examples of feeder cells that may be used in the present invention include, but are not limited to, transgenic animal cell lines, peripheral blood leukocytes (PBLs) treated with various cytokines or compounds, autologous or allogeneic peripheral blood leukocytes (PBLs), T cells, B cells, monocytes, etc. In some embodiments, the feeder cells are K562 feeder cells. In further embodiments, the K562 feeder cells are selected from clone 4 cells, clone 9 cells, and CSTX002 cells.

[0038] In some embodiments, the in vitro activation of natural killer cells is performed in the presence of NK-stimulating exosomes or NIC-stimulating nanoparticles. Exosomes are small extracellular vesicles derived from endosomes with a diameter between 30-100 nm. Tumor-derived exosomes carry many molecules and factors from tumor cells and can be used to stimulate natural killer cells. See Li et al., Exp Cell Res., 363(2):141-150(2018). Nanoparticles can also be used to stimulate natural killer cells. Nanoparticles are particles with a size between 1-2500 nm with a surrounding interface layer. This includes ultrafine nanoparticles with a size of 1-100 nm and fine nanoparticles with a size of 100-2500 nm. Nanoparticles can be prepared using polymers or minerals such as graphene oxide. In some embodiments, the nanoparticles are functionalized to include additional groups, such as antibodies, that help stimulate natural killer cells. See, for example, Loftus et al., Nano Lett., 18(5):3282-3289 (2018).

[0039] Dosage and Administration TGFβi NK cells should be administered and dosed according to good medical practice, taking into account the site and method of administration, the schedule of administration, the age, sex, weight of the patient, the nature and severity of the disorder to be treated or prevented, and other factors known to the physician. The cells may be administered in a single dose or in divided doses. Thus, the pharmacologic "effective amount" for purposes herein is determined by such considerations known in the art. The amount must be effective to achieve improvement, including, but not limited to, improved survival or more rapid recovery, or improvement or elimination of symptoms and other indicators selected as appropriate by the skilled artisan.

[0040] Typically, the dose is about 10×10 6 Approximately 9 x 10 cells / kg of subject weight 6 Cells / kg or less, approximately 8×10 6 Cells / kg or less, approximately 7×10 6 Cells / kg or less, approximately 6×10 6 Cells / kg or less, approximately 5×10 6 In an alternative embodiment, the dose is about 0.25×10 6 cells / kg ~ approx. 5×10 6 cells / kg or about 1×10 6 cells / kg ~ approx. 5×10 6 More preferably, the dose is about 0.25×10 cells / kg. 6 cells / kg, 0.5×10 6 cells / kg, 0.6×10 6 cells / kg, 0.7×10 6 cells / kg; 0.8×10 6 cells / kg; 0.9×10 6 cells / kg; 1.1×10 6 cells / kg; 1.2×10 6 cells / kg; 1.3×10 6 cells / kg; 1.4×10 6 cells / kg; 1.5×10 6 cells / kg; 1.6×10 6cells / kg; 1.7×10 6 cells / kg; 1.8×10 6 cells / kg; 1.9×10 6 cells / kg, or 2 x 10 6 The dose may be, in other embodiments, 0.1 to 1 million cells / kg; or 1 to 2 million cells / kg; or 2 to 3 million cells / kg; or 3 to 4 million cells / kg; or 4 to 5 million cells / kg; or 5 to 6 million cells / kg; or 6 to 7 million cells / kg; or 7 to 8 million cells / kg; or 8 to 9 million cells / kg; or 9 to 10 million cells / kg.

[0041] Exemplary modes of administration include, but are not limited to, injection, infusion, drip, inhalation or ingestion. "Injection" includes, but is not limited to, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, intracerebrospinal and intrasternal injection and infusion. In a preferred embodiment, the composition is administered by intravenous infusion or injection.

[0042] The TGFβi NK cells can be provided in the form of a pharmaceutical composition, comprising an isotonic excipient prepared under sufficiently sterile conditions for human administration. The composition can be sterile. The formulation should be suitable for the mode of administration. For general principles in pharmaceutical formulations, the reader is referred to Cell Therapy: Stem Cell Transplantation, Gene Therapy, and Cellular Immunotherapy, by G. Morstyn & W. Sheridan eds, Cambridge University Press, 1996; and Hematopoietic Stem Cell Therapy, ED Ball, J. Lister & P. ​​Law, Churchill Livingstone, 2000. The choice of cell excipient and any concomitant elements of the composition, including the population of TGFβi NK cells, will be adapted according to the route and device used for administration.

[0043] In some embodiments, the TGFβi NK cells are administered with a pharma- ceutically acceptable carrier. Suitable pharma-ceutically acceptable carriers include, but are not limited to, water, salt solutions (e.g., NaCl), saline, buffered saline, alcohol, glycerol, ethanol, gum arabic, vegetable oils, benzyl alcohol, polyethylene glycol, gelatin, carbohydrates such as lactose, amylose or starch, dextrose, magnesium stearate, talc, silicic acid, viscous paraffin, flavor oils, fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidone, and the like, and combinations thereof. Pharmaceutical preparations can be mixed, if desired, with auxiliary agents that do not adversely react with the active compounds, such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorants, flavorings, and / or aromatic substances.

[0044] The following examples are included to demonstrate preferred embodiments of the invention. It will be appreciated by those skilled in the art that the techniques disclosed in the examples follow representative techniques discovered by the inventors to function well in the practice of the invention, and therefore can be considered to constitute preferred modes for its implementation. However, those skilled in the art will recognize, in light of this disclosure, that many changes can be made in the disclosed specific embodiments and still obtain the same or similar results without departing from the spirit and scope of the invention. EXAMPLES

[0045] Example 1: Imprinting of NK cells to become TGF-β resistant by TGF-β The inventors have generated human NK cells expanded with TGF-β cultures (TGFβi NK) that have reduced sensitivity to TGF-β, most likely through loss of one of the key TGF-β signaling proteins, SMAD3. The inventors demonstrate that: a) TGFβi NK cells have significantly increased IFN-γ, TNF-α and GM-CSF secretion against tumor targets, and b) TGFβi NK cells retain cytokine hypersecretion for at least one month after activation.

[0046] method Cell Culture: NK cells were cultured in RPMI 1640 medium supplemented with Glutamax, 10% FBS, and antibiotics. All cells were routinely tested for mycoplasma contamination using Lonza MycoAlert (Lonza, LT027-58) and found to be negative at all time points. K562 feeder cells were purchased from ATCC (CCL-243) and irradiated at 100 Gy.

[0047] NK cell expansion: Purified primary human NK cells were stimulated 1:2 with irradiated K562 on day 0 and 1:1 on day 7. The K562 cell lines used are indicated in the figure legend as unmodified (parental), expressing 4-1BBL and membrane-bound IL-15 (clone 4), or expressing 4-1BBL and membrane-bound IL-21 (clone 9 or CSTX002). Standard expanded NK cells were supplemented with 50 IU / mL recombinant human IL-2, and resistant (TGFβi NK) expanded NK cells received 50 IU / mL IL-2 and 10 ng / mL TGF-β (Biolegend, 580706). Fresh medium and cytokines were added every 2-3 days. NK cell expansion was measured using CD3 - / CD56 + Calculations were based on the percentage of cells.

[0048] Flow cytometry: Intracellular flow cytometry was performed using BD Cytofix / Cytoperm fixation / permeabilization kit with GolgiStop (BD Biosciences, 554715). Antibodies for the following proteins were used to assess NK phenotype and function: CD3 PeCy7 / APC-H7, CD56 FITC / BV421, NKG2D Pe-CF594 / BV5lO, TRAIL PE / APC / BV421, FasL PE, NKp30 PE / Alexa Fluor 647 / PE-Vio6l5, Granzyme A APC, Granzyme B BV510, Perforin BV421, DNAM-1 BV711, CD 107a BV510, IFN-γ APC, TNF-α BV421, CD16 PE, and Tombo Ghost Dye 510 / 780. Cellular events were acquired on an LSR Fortessa. Flow cytometry gating was determined using cells stained with viability dye only and single color controls were analyzed using FlowJo 7.6.5 / 10 SMAD3 flow.

[0049] Cytotoxicity assay: NK cells were prepared for cytotoxicity assays by overnight incubation in either human IL-2 alone or IL-2 (50 IU / mL) with 10 ng / mL soluble TGF-β (Biolegend). Cytotoxicity assays using the calcein-AM based method were performed at least twice using 3 μg calcein AM / mL / 1,000,000 target cells in complete medium. Calcein assays were performed in the same cytokines as in the overnight incubation of NK cells. Somachi et al., Journal of visualized experiments: JoVE 48, 2540 (2011).

[0050] Intracellular functional flow cytometry: To determine CD 107a expression and degranulation by intracellular cytokine production in response to tumors, 300,000 NK cells were co-cultured in 96-well round-bottom plates with 60,000 tumor cells (E:T ratio of 5:1) or without target for control in 200 μl medium as described for cytotoxicity assays. 1 μl of monensin was added to each sample with CD 107a at the beginning of the assay. Plates were spun at 100g×2 min to promote cell-cell contact and placed in a 37° C. incubator for 3 hours. After 3 hours, medium was removed and staining began for cell surface and intracellular proteins as detailed.

[0051] Cytometric Bead Array (CBA): To determine NK cell release of IFNγ and TNFα, NK cells were cultured as described for intracellular functional flow cytometry, excluding monensin and CD 107a antibodies. After 3 hours of co-culture with tumor targets or 4 hours of stimulation with 10 μg / mL PHA, supernatants were collected and frozen at -75°C until use. On the day of the assay, supernatants were thawed and 50 μL of undiluted supernatant was used with the BD CBA Soluble Protein Master Kit (BD Biosciences, Cat#: 558265), and IFNγ and TNFα Flex Set (BD Biosciences, Cat: 558269, 560112), or MACS Plex Cytokine 12 Kit (Miltenyi, Cat: 130-099-169) according to the manufacturer's instructions. Samples were acquired on a BD LSR II or MACSQuant. The geometric mean for each specimen was determined in Flow Jo v.10.1, and unknown samples were analyzed using the R from known standards for samples acquired with the BD LSR II. 2A standard curve with a mean APC of ≥ 0.9 was used for interpolation. Analysis of MACSQuant acquired specimens was performed using MACSQuantify software (version 2.8, Bergisch GladbacK, Germany). This software uses the mean APC median of the MACSPlex standards and calculates the cytokine concentration in each sample.

[0052] NK cell activation with cytokines: For NK cell stimulation with IL-12, IL-15, and IL-18, primary NK cells were stimulated overnight with 10 ng / mL IL-12 (Biolegend, 573002), 50 ng / mL IL-15 (Biolegend, 570302), and 50 ng / mL IL-18 (Biolegend, 592102) as described, and rested in 1 ng / mL IL-15 for 7-14 days after overnight stimulation with IL-12, IL-15, and IL-18. To determine the effect of IL-2 and TGF-β on cytokine production, NK cells were treated as described, but with the addition of IL-2 and / or TGF-β as indicated for overnight stimulation with IL-12, IL-15, and IL-18, and with 1 ng / mL IL-15 for 7-14 days. To measure cytokine production, NK cells were placed in 1 ng / mL IL-15 overnight only and throughout the assay, and co-cultured with MG63 at a 5:1 ratio or the same number of NK cells as a no target control, and intracellular flow staining was performed as described below.

[0053] RT-PCR / qPCR: RNA from fresh, never frozen, day 14 expanded human NK cells was isolated using the RNAeasy kit, QiaShredder Columns and RNAase-Free DNase set (all Qiagen, 74104, 79654, 79254) and cDNA was synthesized with a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher, 4368814). PCR for the TGF-β pathway was performed on an Applied Biosystems 7900HT using Taqman Fast PCR Mastermix and Human Fast 96-well Pathway Array (ThermoFisher, 4418742).

[0054] Statistical analysis: Statistical analyses were performed using GraphPad Prism 6.0 or 7.0 (La Jolla, CA, USA) as described in each figure legend. P values ​​less than 0.05 were considered significant.

[0055] Results and Discussion IFNγ and TNFα are two proinflammatory cytokines important in antitumor responses, and their production has been reported to be inhibited by TGF-β. To determine the production of proinflammatory cytokines by NK cells, NK cells were cultured with parental (unmodified K562) plus or minus TGFβ for 2 weeks. At the end of the 2 weeks, control and TGFβi NK cells were incubated with tumor targets as described, and supernatants were collected to measure IFN-γ and TNF-α secretion by cytometric bead array. A significant increase in IFN-γ and TNFα secretion was observed in both the presence and absence of TGF-β compared to control expanded NK cells (Figure 1).

[0056] We next determined whether stimulation with K562 or other tumor cells was required for TGFβi cytokine overproduction. To this end, we used IL-12, IL-15, and IL-18, which are well established to activate NK cells in the absence of tumor stimulation. When TGFβ was added to the cultures, NK cells produced increased IFNγ and TNFα in response to tumor stimulation (Figure 2).

[0057] To determine whether other K562 feeder cells were able to generate TGFβi NK cells with enhanced cytokine production, K562 expressing mbIL-15 (Figure 3) or mbIL-21 (Figure 4) were co-cultured with NK cells with or without TGFβ for 2 weeks. Both feeder cells induced TGFβi NK cells with increased cytokine production.

[0058] Because TGFβ has been reported to inhibit NK cell proliferation, we measured proliferation in response to K562mbIL-21 stimulation for 2 weeks. To this end, TGFβ did not significantly affect proliferation (Figure 5).

[0059] Next, we determined the persistence of TGFβi NK cell phenotype and function. TGFβi NK and donor-matched standard NK cells were rested in low-dose IL-2 alone (i.e., TGFβi NK were removed from TGF-β) after completion of 2 weeks of activation. TGFβi NK cells were assessed for secretion of IFN-γ and TNF-α at the end of expansion and 7 to 33 days after activation. Following activation, TGFβi NK cells maintained their increases in IFN-γ and TNF-α secretion both at baseline and with TGF-β treatment (Figure 6).

[0060] In addition, we wanted to determine whether TGFβi NK cells sustained cytokine overproduction in response to various stimuli. To this end, we found that TGFβi NK cells produced increased IFNγ and TNFα in response to medulloblastoma and neuroblastoma cell lines, and that this enhanced production of cytokines was induced upon PHA stimulation, suggesting an innate ability to produce increased antitumor cytokines (Figures 7 and 9).

[0061] The function of SMAD3 as a suppressor of NK cell antitumor function has been elucidated. SMAD3 directly binds to the IFNγ promoter to inhibit IFNγ expression, and SMAD3 - / - Mice had enhanced NK cell function and reduced tumor growth. Therefore, we determined whether SMAD3 was reduced at the protein level by Western blot and found TGFβi NK had significantly reduced SMAD3 protein (Figure 8).

[0062] Furthermore, the cytotoxicity of TGFβi NK cells was tested in vitro in NK cells cultured with parental K562 and in vivo in NK cells expanded with mbIL-2l. Cytotoxicity was unaffected (Figure 10). Indeed, in vivo TGFβi NK cells significantly reduced osteosarcoma growth in the lungs of NSG mice (Figure 11).

[0063] In addition, using RNA-seq analysis, we found that TGFβi NK cells were transcriptionally distinct from control NK cells, suggesting broad changes in cellular phenotype in addition to function (Figure 12).

[0064] In summary, human NK cells expanded with TGF-β culture (TGFβi NK) have reduced sensitivity to TGF-β, most likely via a reduction in one of the key TGF-β signaling proteins, SMAD3. TGFβi NK cells significantly increased IFN-γ, TNF-α and GM-CSF secretion. Surprisingly, and in contrast to previous papers, TGF-β did not inhibit the entire 2-week proliferation of TGFβi NK cells. Bellone et al., J Immunol 155:1066-1073 (1995). The stimulation conditions (IL-2 and IL-15) and time points used in the previous paper to induce proliferation may be key to the observed differences in proliferation. Previous measurements of the effect of TGF-β on NK cell proliferation tested short-term proliferation and not 2-week proliferation. Viel et al., Science signaling 9:ral9(2016). We show that chronic TGF-β stimulation with tumor activator potentially downregulates SMAD3 for survival. neg We propose that these SMAD3s drive the activation of a specific subset of NK cells. neg NK cells are resistant to phosphorylation of SMAD3 by TGF-β in cell culture medium, which may allow for increased proliferation. Oida et al., Journal of immunological method 362:195-198(2010).

[0065] We assessed the ability of TGFβi NK cells to produce IFN-γ and TNF-α, because these cytokines can both inhibit TGF-β and, conversely, TGF-β can inhibit IFN-γ and TNF-α production. Surprisingly, we found significantly increased antitumor IFN-γ and TNF-α secretion in TGFβi NK cells compared to standard NK cells both with and without TGFβ treatment. Previous studies have demonstrated that SMAD3 deletion increases baseline IFN-γ production, and thus, a similar mechanism is likely occurring in TGFβi NK cells that do not express SMAD3. Tang et al., Nat Commun 8:14677(2017). TGF-β has been reported to inhibit TNFα production in primary NK cells (Bellone et al., J Immunol 155:1066-1073(1995)). Unexpectedly, TGFβi NK cells significantly increased secretion of TNF-α with or without TGF-β in the assay medium compared to standard NK cells. Since the control of TNF-α production is less well understood but is also known to be inhibited by TGFβ, finding increased TNF-α secretion in TGFβi NK cells was unexpected.

[0066] While the present invention has been particularly shown and described with respect to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention as encompassed by the appended claims. All patents, publications and references cited in the foregoing specification are hereby incorporated by reference in their entirety. The present invention may include the following aspects. [1] A method for treating cancer or an infectious disease in a subject in need thereof, comprising administering to the subject a therapeutically effective number of transforming growth factor beta (TGF-β) superfamily imprinted natural killer (TGFβi NK) cells. [2] The method according to [1], wherein the subject has an infectious disease. [3] The method according to [2], wherein the infectious disease is a viral infection. [4] The method according to [1], wherein the subject has cancer. [5] The method according to [4], wherein the cancer is a solid tumor. [6] The method according to [4], wherein the cancer is selected from the group consisting of leukemia, lymphoma, rhabdomyosarcoma, brain cancer and bone cancer. [7] The method according to [4], wherein the TGFβi NK cells are resistant to TGF-β. [8] The method of [1], wherein the TGFβi NK cells produce increased amounts of one or more of IFN-γ, TNF-α and GM-CSF. [9] The method of [1], wherein the TGFβi NK cells exhibit reduced levels of SMAD3 protein and / or TGFBR3 protein.

[10] The method of [1], wherein the TGFβi NK cells have a gene expression profile substantially similar to that shown in Figure 12.

[11] The method according to [1], wherein the TGFβi NK cells are administered together with a pharma- ceutically acceptable carrier.

[12] A natural killer (NK) cell or NK cell line that exhibits increased resistance to TGF-β superfamily cytokines.

[13] The NK cell or cell line described in

[12] , wherein the NK cell or cell line exhibits increased resistance to TGF-β.

[14] The NK cell or cell line of

[12] , wherein the NK cell produces increased amounts of one or more of IFN-γ, TNF-α and GM-CSF.

[15] The NK cell or cell line described in

[12] , wherein the NK cell exhibits reduced levels of SMAD3 protein and / or TGFBR3 protein.

[16] The NK cell or cell line described in

[12] , wherein the NK cell has a gene expression profile substantially similar to that shown in Figure 12.

[17] The NK cell or cell line described in

[12] , wherein the NK cell is prepared by in vitro activation of natural killer cells in the presence of TGF-β.

[18] The NK cell or cell line described in

[12] , wherein the NK cell is a human NK cell.

[19] The NK cell or cell line described in

[12] , wherein the NK cell is a canine NK cell.

[20] A method for generating a TGF-β superfamily imprinted natural killer (TGFβi NK) cell line, comprising in vitro activation of natural killer cells in the presence of a TGF-β superfamily cytokine.

[21] The method of

[20] , wherein the TGFβi NK cell line is activated in the presence of TGF-β.

[22] The method of

[20] , further comprising in vitro activation of natural killer cells in the presence of leukemic feeder cells.

[23] The method according to

[22] , wherein the feeder cells are K562 feeder cells.

[24] The method according to

[23] , wherein the K562 feeder cells are genetically modified to express costimulatory proteins and / or cytokines.

[25] The method of

[20] , further comprising in vitro activation of natural killer cells in the presence of NK-stimulating exosomes or NK-stimulating nanoparticles.

Claims

1. 1. A pharmaceutical composition for treating cancer or an infectious disease, comprising an expanded population of NK cells having increased resistance to TGF-β compared to naturally occurring NK cells, said expanded population of NK cells being expanded in vitro in the presence of IL-2, TGF-β and leukemia feeder cells, said feeder cells being K562 feeder cells genetically modified to express 4-1BBL and membrane-bound IL-21.

2. The pharmaceutical composition of claim 1 , wherein the cancer is a solid tumor.

3. 2. The pharmaceutical composition of claim 1, wherein the cancer is selected from the group consisting of leukemia, lymphoma, rhabdomyosarcoma, brain cancer and bone cancer.

4. The pharmaceutical composition of claim 1 , wherein the expanded population of NK cells produces increased amounts of one or more of IFN-γ, TNF-α and GM-CSF.

5. The pharmaceutical composition of claim 1 , wherein the expanded population of NK cells exhibits reduced levels of SMAD3 protein and / or TGFBR3 protein.

6. 2. The pharmaceutical composition of claim 1, wherein the expanded population of NK cells exhibits increased expression of SCUBE1, MY07A, KLF3, WIPF3 and EPHA1, or decreased expression of CD300A, SGSM1, SMAD3, TBX21, GZMK, TGFBR3 and GZMA.

7. The pharmaceutical composition according to any one of claims 1 to 6, comprising a pharma- ceutically acceptable carrier.

8. A natural killer (NK) cell or NK cell line exhibiting increased resistance to TGF-β, wherein the NK cell or NK cell line has increased resistance to TGF-β compared to naturally occurring NK cells; 1) prepared by a) K562 feeder cells genetically modified to express 4-1BBL and membrane-bound IL-21, and b) in vitro activation of NK cells in the presence of IL-2 and TGF-β; 2) produce increased amounts of one or more of IFN-γ, TNF-α and GM-CSF; and / or 3) NK cells or NK cell lines exhibiting reduced levels of SMAD3 and / or TGFBR3 proteins.

9. The NK cell or NK cell line of claim 8, wherein the NK cells exhibit increased expression of SCUBE1, MY07A, KLF3, WIPF3 and EPHA1, or decreased expression of CD300A, SGSM1, SMAD3, TBX21, GZMK, TGFBR3 and GZMA.

10. The NK cell or NK cell line of claim 8 or 9, wherein the NK cell is a human NK cell or a canine NK cell.

11. 1. A method for generating a population of expanded NK cells having increased resistance to TGF-β compared to naturally occurring NK cells, comprising in vitro activation of natural killer cells in the presence of leukemic feeder cells, IL-2 and TGF-β, wherein the feeder cells are K562 feeder cells genetically modified to express 4-1BBL and membrane-bound IL-21.

12. The method of claim 11, further comprising in vitro activation of natural killer cells in the presence of NK-stimulating exosomes or NK-stimulating nanoparticles.

Citation Information

Patent Citations

  • Methods and compositions for natural killer cells

    JP2017532353A

  • Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same

    US20170056448A1